Table 2.

Phase I/II clinical trials of CTLA-4 blockade

AntibodiesDoseCancerNo. of casesNo. of objective responsesReference
MDX-0103 mg/kg, 1.5 mg/kg every 4 weeksLymphoma42(63)
Colon30
Prostate40
MDX-0103 mg/kgProstate142 (≥50% decrease of prostate-specific antigen)(58)
MDX-0103 mg/kg every 3 weeksRenal211 partial response(66)
3 mg/kg, 1 mg/kg every 3 weeksRenal385 partial responses
MDX-0103 mg/kgMelanoma70(57)
Ovarian20
MDX-0103 mg/kg every 4 weeksMelanoma372 partial responses(69)
MDX-010 + dacarbazineMelanoma351 complete response
5 partial responses
MDX-0101-3 mg/kgRenal617(64)
MDX-010 ± gp100 peptide1-9 mg/kgMelanoma13720
MDX-010 + gp100 peptide3 mg/kg every 3 weeksMelanoma142 complete responses(61)
1 partial response
MDX-010 + gp100 peptide3 mg/kg every 3 weeksMelanoma292 complete responses(60)
2 partial responses
1-3 mg/kg, 1 mg/kg every 3 weeksMelanoma273 partial responses
MDX-010 + IL-21 mg/kg × 3-6Melanoma61 partial response(65)
2 mg/kg × 3-7Melanoma31 complete response
3 mg/kg × 1-9Melanoma272 complete responses
4 partial responses
MDX-010 + peptide0.3-3 mg/kg every 3 weeksMelanoma197(62)
MDX-010 + GVAX3 mg/kgProstate65 (≥50% decrease of prostate-specific antigen)(70)
CP-675,2060.01-15 mg/kg × 1Melanoma342 complete responses(59)
2 partial responses
Renal40
Colon10
CP-675, 2063-10 mg/kg every 4 weeksMelanoma141(67)
CP-675, 20610 mg/kg every 4 weeksMelanoma163(68)
15 mg/kg every 12 weeksMelanoma102